Questcor Pharmaceuticals (Nasdaq: QCOR ) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Questcor Pharmaceuticals's revenues will expand 64.3% and EPS will grow 60.3%.
The average estimate for revenue is $157.7 million. On the bottom line, the average EPS estimate is $0.93.
Last quarter, Questcor Pharmaceuticals reported revenue of $160.5 million. GAAP reported sales were much higher than the prior-year quarter's $75.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $1.03. GAAP EPS of $1.03 for Q4 were 115% higher than the prior-year quarter's $0.48 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 94.3%, 40 basis points worse than the prior-year quarter. Operating margin was 59.0%, 240 basis points better than the prior-year quarter. Net margin was 38.6%, 330 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $680.9 million. The average EPS estimate is $3.98.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 488 members out of 548 rating the stock outperform, and 60 members rating it underperform. Among 126 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 99 give Questcor Pharmaceuticals a green thumbs-up, and 27 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $41.86.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Questcor Pharmaceuticals. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Questcor Pharmaceuticals to My Watchlist.